Mammoth Biosciences, based in Brisbane, Calif., was founded in 2017 by Trevor Martin, the company’s CEO, and Janice Chen, Lucas Harrington, and Jennifer Doudna. The company, which was last valued at $1.08 billion in September 2021, is developing novel CRISPR systems to cure and detect diseases. CRISPR is a tool that can allow researchers to alter DNA sequences and modify gene function.
In November, the company was named to Fast Company’s 2022 list of the “Next Big Things in Tech.” In September 2021, the company raised $150 million in Series D financing from a group of investors including Redmile Group, Foresite Capital, Greenspring Associates and Senator Investment Group.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Mammoth Biosciences is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
Mammoth Biosciences has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.
Mammoth Biosciences is privately held company and is not publicly traded, therefor investing in Mammoth Biosciences pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.
To determine the value of your Mammoth Biosciences shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Mammoth Biosciences shares. You can also learn more about how to sell your private shares before getting started.
Yes, you can seek to sell shares in Mammoth Biosciences while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.
Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
---|---|---|---|---|
4/22/2024 | Series D-2 |
$107.74MM raised | $XXX.XX | $XXX.XX |
9/9/2021 | Series D and D-1 |
$150MM raised | $XXX.XX | $XXX.XX |
11/4/2020 | Series C and C-1 |
$45.11MM raised | $XXX.XX | $XXX.XX |
1/30/2020 | Series B and B-1 |
$44.18MM raised | $XXX.XX | $XXX.XX |
8/8/2018 | Series A |
$18.1MM raised | $XXX.XX | $XXX.XX |